A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC)
The main purpose of this study is to evaluate safety and tolerability of LY2157299 when combined with sorafenib in Japanese hepatocellular carcinoma (HCC) participants.
Hepatocellular Carcinoma
DRUG: LY2157299|DRUG: Sorafenib
Number of Participants with LY2157299 Dose-Limiting Toxicities (DLT), Cycle 1 (28 days)
Pharmacokinetics (PK): Area Under the Plasma Concentration-time Curve (AUC) of LY2157299, Cycle 1 Day1: predose through 6 hours post dose; Cycle1 Day14: predose through 24 hours post dose|PK: Maximum Observed Plasma Concentration (Cmax) of LY2157299, Cycle 1 Day 1: Predose through 6 hours post dose; Cycle 1 Day 14: Predose through 24 hours post dose|Time to Progression (TTP), Baseline to objective progressive disease (estimated as 6 months)|Progression-free Survival (PFS), Baseline to objective progressive disease or death (estimated as 6 months)|The Number of Participants with Best Response of Partial Response (PR), Complete Response (CR), Stable Disease (SD), or Progressive Disease (PD), Baseline to objective progressive disease (estimated as 6 months)
The main purpose of this study is to evaluate safety and tolerability of LY2157299 when combined with sorafenib in Japanese hepatocellular carcinoma (HCC) participants.